| Field | Specification |
|---|---|
| Target | |
| Alternative names | Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1; Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit; Ribophorin I; RPN-I; Ribophorin-1; RPN1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human RPN1 recombinant protein (Position: D196-H495). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (gene RPN1) in human samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 68.6 kDa, and the supplier reports an observed band at about 69 kDa.
Ribophorin I (RPN1) is a subunit of the oligosaccharyltransferase (OST) complex in the endoplasmic reticulum membrane. OST transfers a preassembled glycan from dolichol pyrophosphate to asparagine residues in Asn-X-Ser/Thr motifs of newly made proteins, the first step of N-linked glycosylation, working next to the Sec61 translocon.
| Target | Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (gene RPN1; UniProt P04843, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 68.6 kDa |
| Observed MW | 69 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human K562 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, human lung adenocarcinoma tissue, human placenta tissue, human rectum adenocarcinoma tissue, human testicular seminoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): HepG2 cells.
Immunogen
Recombinant human RPN1 fragment (Asp196–His495), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 in the endoplasmic reticulum membrane and melanosome. Tissue expression noted by UniProt (human): Expressed in all tissues tested. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
